Shares of Olema Pharmaceuticals, Inc. (OLMA) skyrocketed by 139.79% in Tuesday's trading session, following a series of positive developments that have significantly boosted investor confidence in the company's prospects.

The rally was primarily triggered by JPMorgan's bullish stance on the stock. The investment bank raised its price target for Olema Oncology to $32 from $29, while maintaining an Overweight rating. This upgrade reflects growing optimism about Olema's potential in the oncology sector, particularly in developing therapies for women's cancers.

Adding fuel to the fire, Roche Holdings AG announced positive phase 3 results from its lidERA Breast Cancer study of giredestrant in early-stage breast cancer. This news has broader implications for the sector, including Olema, whose lead drug candidate, palazestrant, is also a selective estrogen receptor degrader (SERD) currently in two Phase 3 clinical trials. The success of Roche's trial, being the first to demonstrate a significant benefit of a SERD in the adjuvant setting, has increased confidence in the potential of similar drugs, including Olema's palazestrant. As a result, some analysts, including those at Oppenheimer, have increased their probability of success estimates for Olema's drug candidate and raised their price forecasts accordingly.